Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Power of two: combination of therapeutic approaches involving glucose transporter (GLUT) inhibitors to combat cancer

Biochimica et Biophysica Acta (BBA) - Reviews on Cancer(2020)10.1016/j.bbcan.2020.188457Source: DataRank Database

Power of two: combination of therapeutic approaches involving glucose transporter (GLUT) inhibitors to combat cancer is a research paper published in Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2020). On theSindex it has a DataRank of 0. It has been cited 78 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access78 citations

Free full text

Cite:

Linked data & code

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (1 grants)Impact (FWCI 2.69)OA: greenTopics (39)Linked Datasets (2)DataCite Reuse (2)IDs (PubMed, OpenAlex)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (2/2)

Has DOI
Indexed in repositories

Accessible (1/2)

Open Access

Interoperable (2/2)

DataCite relations
Linked datasets

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (6)

Neha Upadhyay,Cristina V. Iancu ORCID,Vadim S. Pokrovsky ORCID,Jun‐yong Choe,C. S. Ramaa ORCID

Live enrichment

PubMed:33096154 OpenAlex:https://openalex.org/W3094068511

National Institutes of Health

Grant: 3R01GM123103-02S1

Ligand specificity in human glucose transporters GLUT1-5 and GLUT9

FWCI

2.69

Citation Percentile

0.9%

Citation Trend

2021

2022

2023

2024

2025

2026

greenLicense: Elsevier TDM

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/7704680

publisherhttps://api.elsevier.com/content/article/PII:S0304419X20301761?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S0304419X20301761?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.bbcan.2020.188457

Fields of Study

Cancer, Hypoxia, and MetabolismMetabolism, Diabetes, and CancerPancreatic and Hepatic Oncology Research0301 basic medicine0303 health sciences03 medical and health sciences

MeSH Terms

AnimalsAntineoplastic AgentsClinical Trials as TopicDrug SynergismGlycolysisHumansNeoplasmsMolecular StructureGlucose Transport Proteins, Facilitative

Keywords

Glucose transporterGlucose uptakePharmacologyCombination therapyCancerPaclitaxelMedicineCancer researchInternal medicineInsulinClinical Trials as TopicMolecular StructureGlucose transporters (GLUTs)Glucose Transport Proteins, Facilitative610Antineoplastic AgentsDrug SynergismDrug synergyGLUT inhibitorsNeoplasmsAnimalsHumansGlycolysisCombination strategy

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being

Additional file 1 of Exploring the role of the disulfidptosis-related gene SLC7A11 in adrenocortical carcinoma: implications for prognosis, immune infiltration, and therapeutic strategies

10.6084/m9.figshare.26635128.v1figshare

Additional file 1 of Exploring the role of the disulfidptosis-related gene SLC7A11 in adrenocortical carcinoma: implications for prognosis, immune infiltration, and therapeutic strategies

10.6084/m9.figshare.26635128figshare